Home Health Herpes-Dementia Link; How COVID Affects the Brain; FDA to Decide on Duchenne Drug

Herpes-Dementia Link; How COVID Affects the Brain; FDA to Decide on Duchenne Drug

by News7

A prospective study in Sweden reported a link between herpes simplex virus and dementia. (Journal of Alzheimer’s Disease)

Researchers differentiated people with Parkinson’s disease from healthy controls with 68% accuracy using retinal fundus imaging. (Scientific Reports)

Clinicians need to consider the political context of preclinical diagnoses of neurodegenerative diseases, ethicists argued. (JAMA Neurology)

German researchers showed that SARS-CoV-2 did not persist in brain cells and supported the idea that COVID’s neurologic complications may be due to inflammatory immune reactions. (Nature Neuroscience)

More than half of people with long COVID reported experiencing cognitive symptoms daily, according to a U.S. survey. (JAMA Network Open)

Data from the University of Washington showed SARS-CoV-2 infection was linked with a significant increase in incident fatigue and chronic fatigue. (Emerging Infectious Diseases)

In a mouse model, traumatic brain injury led to changes in functional connectivity beyond the immediate area of impact. (Cerebral Cortex)

The FDA set a June 21 deadline to decide whether to expand delandistrogene moxeparvovec (Elevidys)’s indication for Duchenne muscular dystrophy and convert the treatment’s accelerated approval to traditional approval, Sarepta said.

The phase II HIMALAYA study of SAR443820 (DNL788) in amyotrophic lateral sclerosis didn’t meet its primary endpoint, but the investigational RIPK1 inhibitor will continue being studied in multiple sclerosis, according to Sanofi and Denali Therapeutics.

Full data from the phase IIIb ELEVATE trial showing that atogepant (Qulipta) reduced mean monthly migraine days in treatment-resistant episodic migraine were published in Lancet Neurology. Trial findings previously were presented at the 2023 American Academy of Neurology meeting.

Musician and songwriter Brian Wilson has a “major neurocognitive disorder” and is taking medication for dementia, according to a petition filed to place the 81-year-old Beach Boys co-founder in conservatorship. (AP)

Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more. Follow

Source : MedPageToday

You may also like